Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:00:08 17/07/2024 pm IST			5-day change	1st Jan Change
99.06 ^CHF	+0.16%		+0.77%	+16.72%

15/07	Brace for a flurry of speeches from Fed officials
15/07	European companies cut jobs as economy sputters	RE

ThromboGenics NV announced that it has received €10 million in funding from Novartis AG

January 26, 2018

On January 26, 2018, ThromboGenics NV (ENXTBR:THR) closed the transaction. The company issued 2,177,226 shares in the transaction. The investor acquired 5.7% stake in the company.

Latest news about Novartis AG

Brace for a flurry of speeches from Fed officials	15/07
European companies cut jobs as economy sputters	15/07	RE
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	15/07	MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings	13/07	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	12/07	MT
Global markets live: KKR, Apple, Tesla, Oracle, McDonald's...	12/07
Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected	11/07	MT
Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected	11/07	MT
Markets Powered by Alternating Current	10/07
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	10/07	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	10/07	MT
European companies cut jobs as economy sputters	09/07	RE
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief	08/07	MT
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	05/07	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	05/07	MT
NOVARTIS AG : Berenberg sticks Neutral	03/07	ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	03/07	DJ
NOVARTIS AG : Receives a Buy rating from Jefferies	02/07	ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	02/07	ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector	02/07	MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	01/07	MT
New semester, new state of mind	01/07
NOVARTIS AG : Gets a Buy rating from Goldman Sachs	01/07	ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse	24/06	RE
NOVARTIS AG : Barclays reaffirms its Sell rating	24/06	ZD

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

10:30am - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 10:54 pm IST

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 04:48 pm IST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 08:02 pm IST

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.9 USD

Average target price

112.7 USD

Spread / Average Target

+0.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+16.72%	23TCr
ELI LILLY AND COMPANY	+55.35%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.10%	36TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	30TCr
ASTRAZENECA PLC	+15.51%	24TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr
SANOFI	+2.52%	13TCr

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

ThromboGenics NV announced that it has received €10 million in funding from Novartis AG

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals